Cargando…
A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
Background: This study aimed to assess the safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide, for people living with HIV (PWH). Methods: A total of 57 PWH of ≥20 years of age who are on stable ant...
Autores principales: | Cheng, Shu-Hsing, Lien, Chia En, Hsieh, Szu-Min, Cheng, Chien-Yu, Liu, Wang-Da, Lo, Ching-Lung, Ko, Wen-Chien, Chen, Yen-Hsu, Huang, Ching-Tai, Chang, Hsiao-Ting, Hwang, Shinn-Jang, Wang, Ning-Chi, Liu, Ming-Che, Lee, Yu-Lin, Tai, I-Chen, Estrada, Josue Antonio Garcia, Lin, Tzou-Yien, Lee, Wen-Sen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863561/ https://www.ncbi.nlm.nih.gov/pubmed/36679862 http://dx.doi.org/10.3390/vaccines11010018 |
Ejemplares similares
-
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022) -
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
por: Hsieh, Szu-Min, et al.
Publicado: (2021) -
Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022) -
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
por: Liu, Luke Tzu-Chi, et al.
Publicado: (2022) -
Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)